Du 26 au 28 mars 2019 à Paris Porte de Versailles (Hall 4), Forum Labo Paris, le salon des fournisseurs de matériels et services pour le laboratoire va promouvoir dix startups à fort potentiel sur le Lab’startup village. HCS Pharma Read more…
We are very happy to annonce a new distributor for the Japan and Taiwan areas, Tokyo Future style, Inc. Tokyo Future Style,Inc. is an international trading company focusing on reagents and materials needed for research in the field of biomedical Read more…
Du 26 au 28 mars 2019 à Paris Porte de Versailles (Hall 4), Forum Labo Paris, le salon des fournisseurs de matériels et services pour le laboratoire, événement du CIFL (1), va promouvoir dix startups à fort potentiel en les Read more…
Following the success of BIOMIMESYS® range of products, which accurately and physiologically reproduces the microenvironment of liver, adipose and cancerous tissues, HCS Pharma is expanding its product range with BIOMIMESYS® Brain, an exclusive and innovative system for the 3D cell Read more…
Après le succès de la gamme BIOMIMESYS® reproduisant de manière précise et physiologique le microenvironnement du foie, des tissus adipeux et des tissus cancéreux, HCS Pharma étend sa gamme avec BIOMIMESYS® Brain, un système exclusif et innovant permettant la culture Read more…
Most potential drug candidates (90%) fail within the clinical trials, mainly because of lack of efficacy. What if the pharmaceutical industry uses predictive human in vitro models in early drug discovery ? View and download on Slideshare (low quality) https://fr.slideshare.net/hcspharma/a-groundbreaking-3d-cell-culture-technology-for-hcs-biomimesys-hydroscaffold Ask Read more…
We are developing a new BIOMIMESYS® hydroscaffold for neuronal cells. First results are very promising because neurons grow and form neurites. Moreover cells lived longer than in monolayer culture. We are currently finalizing this new hydroscaffold to find the best Read more…
Source : Direct Effect of Bevacizumab on Glioblastoma Cell Lines In Vitro Abstract Bevacizumab is a humanized monoclonal antibody directed against the pro-angiogenic factor vascular and endothelial growth factor-A (VEGF-A) used in the treatment of glioblastomas. Although most patients respond Read more…
Source : Elastin‐derived peptides: Matrikines critical for glioblastoma cell aggressiveness in a 3‐D system Abstract In the most common primary brain tumors, malignant glioma cells invade the extracellular matrix (ECM) and proliferate rapidly in the cerebral tissue, which is mainly Read more…
Source : Three Dimensional Tumor Engineering by Co-Culture of Breast Tumor and Endothelial Cells Using a Hyaluronic Acid Hydrogel Model Abstract Besides tumor cells, the microenvironment harbors a variety of host-derived cells. To date, the most successful tissue engineering approaches Read more…
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.